| |
| |
|
| Insider
Information: |
Sachdev Amit |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
71,325 |
|
|
Indirect Shares
|
7,447 |
|
|
| Direct
Value |
$24,204,134 |
|
|
|
Indirect Value
|
$3,257,988 |
|
|
| Total
Shares |
78,772 |
|
|
| Total
Value |
$27,462,122 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
EVP Chief Patient & Ex... |
2024-02-26 |
55,325 |
2024-02-26 |
7,447 |
Premium* |
|
|
Celladon Corp |
CLDN |
|
2022-03-11 |
16,000 |
2020-03-12 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
192 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 8
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CLDN |
Celladon Corp |
Director |
– • – |
2020-03-12 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2020-12-08 |
4 |
GD |
$0.00 |
$0 |
I/I |
3,391 |
7,368 |
0 |
- |
|
| CLDN |
Celladon Corp |
Director |
– • – |
2021-03-12 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
10,000 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2022-05-17 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,672 |
11,052 |
0 |
- |
|
| CLDN |
Celladon Corp |
|
• • – |
2022-03-11 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
16,000 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Public Policy,Gov Affairs |
• – – |
2007-07-23 |
4 |
A |
$0.01 |
$170 |
D/D |
17,000 |
17,000 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Public Policy,Gov Affairs |
• – – |
2007-11-07 |
4 |
B |
$24.72 |
$24,720 |
D/D |
1,000 |
18,000 |
2.74 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
• – – |
2012-11-16 |
4 |
AS |
$41.29 |
$94,430 |
D/D |
(2,287) |
18,821 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
• – – |
2012-09-13 |
4 |
AS |
$55.86 |
$2,150,304 |
D/D |
(38,281) |
21,108 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
• – – |
2012-09-14 |
4 |
AS |
$58.00 |
$552,798 |
D/D |
(9,531) |
21,108 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
• – – |
2012-09-21 |
4 |
AS |
$59.00 |
$562,329 |
D/D |
(9,531) |
21,108 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Global Gov. Strategy |
• – – |
2013-12-12 |
4 |
AS |
$65.47 |
$166,425 |
D/D |
(2,542) |
26,561 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Public Policy,Gov Affairs |
• – – |
2008-02-07 |
4 |
A |
$0.01 |
$102 |
D/D |
10,166 |
28,166 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Public Policy,Gov Affairs |
• – – |
2008-11-18 |
4 |
AS |
$26.20 |
$20,724 |
D/D |
(791) |
28,166 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
• – – |
2013-02-05 |
4 |
A |
$0.01 |
$102 |
D/D |
10,166 |
28,987 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Global Gov. Strategy |
• – – |
2013-07-05 |
4 |
AS |
$80.65 |
$5,030,805 |
D/D |
(61,907) |
28,987 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Global Gov. Strategy |
• – – |
2013-07-11 |
4 |
AS |
$84.00 |
$588,000 |
D/D |
(7,000) |
28,987 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Global Gov. Strategy |
• – – |
2013-07-12 |
4 |
AS |
$85.00 |
$3,225,000 |
D/D |
(37,500) |
28,987 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Global Gov. Strategy |
• – – |
2013-07-19 |
4 |
AS |
$88.00 |
$1,973,250 |
D/D |
(22,250) |
28,987 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
• – – |
2012-09-14 |
4 |
OE |
$32.16 |
$306,517 |
D/D |
9,531 |
30,639 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
• – – |
2012-09-21 |
4 |
OE |
$32.16 |
$306,517 |
D/D |
9,531 |
30,639 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
• – – |
2012-05-07 |
4 |
AS |
$52.13 |
$3,062,638 |
D/D |
(58,750) |
31,108 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2021-11-15 |
4 |
AS |
$186.78 |
$9,547 |
D/D |
(51) |
31,928 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
• – – |
2020-02-25 |
4 |
AS |
$230.00 |
$788,402 |
D/D |
(3,376) |
32,915 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, CRO |
• – – |
2019-05-15 |
4 |
AS |
$165.41 |
$10,090 |
D/D |
(61) |
33,416 |
0 |
- |
|
192 Records found
|
|
Page 1 of 8 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
